# Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC

> **NCT07244016** · — · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Extensive-stage Small-cell Lung Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07244016
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-20
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-07-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07244016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07244016, "Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07244016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*